Ignite Creation Date:
2024-05-06 @ 3:15 AM
Last Modification Date:
2024-10-26 @ 11:31 AM
Study NCT ID:
NCT02248532
Status:
COMPLETED
Last Update Posted:
2018-01-23
First Post:
2014-09-16
Brief Title:
Repetitive Intramyocardial CD34 Cell Therapy in Dilated Cardiomyopathy REMEDIUM
Sponsor:
University Medical Centre Ljubljana
Organization:
University Medical Centre Ljubljana
Study Overview
Official Title:
Repetitive Intramyocardial CD34 Cell Therapy in Dilated Cardiomyopathy
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REMEDIUM
Brief Summary:
The goal of REMEDIUM project is to develop personalized stem cell therapy for patients with chronic heart failure due to dilated cardiomyopathy DCM The main focus of the project is 1 on repetitive administration of cell therapy that would allow for long-lasting improvements in heart function and outcome in this patient population In parallel the investigators aim to 2 develop a standardized patient-specific stem cell product that could be cryopreserved and stored in a stem cell bank for prolonged time periods and used for therapeutic application when clinically indicated By using a unique multimodality imaging platform the goal of this project is also to 3 define standardized clinical criteria that would serve as a guideline for evaluation of the effects of stem cell therapy in future clinical trials and everyday clinical settings Finally to improve the clinical implementation of cell therapythe investigators aim to 4 develop a stem cell delivery technique that could be used to treat both left and right and ventricular failure and could be implemented in a standardized fashion designed for a widespread clinical use
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None